Copyright
©2013 Baishideng Publishing Group Co.
World J Obstet Gynecol. Nov 10, 2013; 2(4): 167-175
Published online Nov 10, 2013. doi: 10.5317/wjog.v2.i4.167
Published online Nov 10, 2013. doi: 10.5317/wjog.v2.i4.167
Ref. | Patients (neoadjuvant) | Type of NACT | HIPEC (technique, drug and dose, temperature, lenght of infusion time) | Period | Country |
Steller et al[46] | 2 | C, carboplatin 800-1200 mg/m2, 41-43 °C, 90 min | NR | United States | |
Look et al[44] | 4 | O, doxorubicin, NR, NR | 1988-2001 | Singapore | |
Piso et al[45] | 8 (1) | iv TPB | O, cisplatin 75 mg/m2, NR, 90 min | 1995-1999 | Germany |
Reichman et al[43] | 9 (9) | iv PB | O, cisplatin 50 mg/m2, 40 °C, 90 min | 2001-2004 | United States |
Rufián et al[42] | 19 | O, paclitaxel 60 mg/m2, 41-43 °C, 60 min | 1997-2004 | Spain | |
Roviello et al[47] | 45 (31) | iv TPB | C, mitomycin C 25 mg/m2 + cisplatin 100 mg/m2, 41-43 °C, 60 min | 2000-2009 | Italy |
Pavlov et al[39] | 31 | C, doxorubicin 0.1 mg/kg (+ EPIC 15 mg/m2× 5 d), NR, NR | 1995-2007 | Serbia | |
Guardiola et al[40] | 31 (31) | iv TPB | O, cisplatin 180 mg, 37 °C, 120min | 2003-2006 | France |
Di Giorgio et al[41] | 22 (4) | iv TPB | C, cisplatin 75 mg/m2, 42-43 °C, 60 min | 2000-2007 | Italy |
Lim et al[48] | 30 (14) | NR | C, cisplatin 75 mg/m2, 41.5 °C, 90 min | 2007-2009 | Korea |
Frenel et al[49] | 7 (7) | iv TPB | O, oxaliplatin, 360-460 mg/m2, 41-43 °C, 30 min | 2005-2008 | France |
Muñoz-Casares et al[50] | 10 (10) | ip TB (+ in 5 pts iv PB) | O, paclitaxel, 60 mg/m2, 41-43 °C, NR | 2004-2009 | Spain |
Parson et al[38] | 51 | C, carboplatin 1000 mg +mitomycin C 30 mg, 41-42 °C, 60-120 min | 1996-2009 | United States | |
Deraco et al[32] | 26 | C, cisplatin 40 mg/L of perfusate + doxorubicin 15 mg/L of perfusate), 42.5 °C, 90 min | 2004-2010 | Italy |
- Citation: Lotti M, Busci LM, Campanati L, Catena F, Coccolini F, Bakrin N, Iaco PD, Ercolani G, Grosso G, Pisano M, Poiasina E, Rossetti D, Rossi M, Zamagni C, Bertoli P, Pinna AD, Frigerio L, Ansaloni L. Cytoreductive surgery and HIPEC after neoadjuvant chemotherapy for advanced epithelial ovarian cancer. World J Obstet Gynecol 2013; 2(4): 167-175
- URL: https://www.wjgnet.com/2218-6220/full/v2/i4/167.htm
- DOI: https://dx.doi.org/10.5317/wjog.v2.i4.167